S3V
VASCULAR TECHNOLOGIES

3V SIRIS*

Rapamycin Eluting Coronary Stent Implantation System



Uncompromised Quality
Unsurpassed Value

* With German Collaboration

3V SIRIS

Rapamycin Eluting Coronary Stent Implantation System

CE 0086

S3V VASCULAR TECHNOLOGIES

250 Patients
Follow - up for over 2 years

Zero Stent Thrombosis
during entire implant period

Inert Ion Technology
High speed bombardment of ions
under vacuum to prevent ion leaching

Late Thrombosis
0% percent at 24 Months

Optimal Loading Dose
Optimum Sirolimus Loading dose of
2.0 micro gram per square millimeter

INERT - TECHNOLOGY





High speed bombardment of ions
under vacuum onto alloy's surface

Inert Ion Technology

Under vacuum, ions are shot with high load of energy on the stent surface so that, the ions are implanted within the metal lattice under the alloy's surface.

The INERT - Technology alters the stent surface into highly biocompatible alloy.

Uncompromised Quality

Unsurpassed Value

3V SIRIS

Rapamycin Eluting Coronary Stent Implantation System

CE 0086

S3V VASCULAR TECHNOLOGIES

Novel Drug Delivery System

The Rapamycin (Sirolimus) Eluting Stent Implantation System is an inert stent [Inert Technology] with a completely biodegradable polymer coating which contains Sirolimus as highly effective drug for preventing early thrombotic and re-stenotic events. Absorption of carrier coating and drug takes place simultaneously leaving an inert stent platform behind.

Full bio-degradation after 6 weeks in-vivo



REM - picture figure 1:
Sirolimus Eluting Stent 14 Days Implanted



REM - picture figure 2:
Sirolimus Eluting Stent 28 Days Implanted



REM - picture figure 3:
Sirolimus Eluting Stent 42 Days Implanted



REM - picture figure 4:
Sirolimus Eluting Stent 84 Days Implanted



3V SIRIS



USFDA Approved Everolimus Stent

Parameters	3V SIRIS	USFDA Approved Everolimus Stent
Uncovered Stent Struts at 4 months	6.8%	17.5%
Stent Thrombosis	0%	0.6%
MI %	2.3%	5.7%

Coating

The polymer used is Poly-lactic-co-glycolic acid (PLGA) which will degrade 100% into carbon dioxide and water. It does not need any other auxiliary polymer like parylene C.
The controlled polymer degradation and release of Sirolimus is designed to terminate simultaneously and is completed within less than 6 months. This covers exactly the time where the drug is needed at most and is tailored uniquely to various immune response reactions that occur after stent implantation.

Uncompromised Quality

Unsurpassed Value

3V SIRIS

Rapamycin Eluting Coronary Stent Implantation System

CE 0086

S3V VASCULAR TECHNOLOGIES

Product Ranges for 3V SIRIS

Stent Length (mm)	Balloon Diameter (mm)							
	2.00	2.25	2.50	2.75	3.00	3.25	3.50	4.00
10	SR110	SR210	SR310	SR410	SR510	SR610	SR710	SR810
14	SR114	SR214	SR314	SR414	SR514	SR614	SR714	SR814
18	SR118	SR218	SR318	SR418	SR518	SR618	SR718	SR818
24	SR124	SR224	SR324	SR424	SR524	SR624	SR724	SR824
28	SR128	SR228	SR328	SR428	SR528	SR628	SR728	SR828
34	SR134	SR234	SR334	SR434	SR534	SR634	SR734	SR834
38	SR138	SR238	SR338	SR438	SR538	SR638	SR738	SR838

Contact Information:
S3V Vascular Technologies (P) Ltd.
#772, Balaji Chambers,
New Kalidasa Road, Vijaynagar 1st Stage,
Mysore - 570 017, Karnataka, INDIA.
Tel: +91 821 2410016
E-mail: info@s3vvascular.com
Web: www.s3vvascular.com

Manufacturing Site:
Boschstrasse 16,
21423 Winsen,
Germany.